BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Zhu JJ, Wilding JPH, Gu XS. Combining GLP-1 receptor agonists and SGLT-2 inhibitors for cardiovascular disease prevention in type 2 diabetes: A systematic review with multiple network meta-regressions. World J Diabetes 2024; 15(10): 2135-2146 [PMID: 39493569 DOI: 10.4239/wjd.v15.i10.2135]
URL: https://www.wjgnet.com/1948-9358/full/v15/i10/2135.htm
Number Citing Articles
1
Gökhan Koker, Muhammed Ali Coskuner. Comment on “SGLT2i–GLP-1RA combination and cardiovascular outcomes in T2D with ACS”International Journal of Cardiology 2025; : 133700 doi: 10.1016/j.ijcard.2025.133700
2
Vanishri Ganakumar, Cornelius J Fernandez, Joseph M Pappachan. Antidiabetic combination therapy and cardiovascular outcomes: An evidence-based approachWorld Journal of Diabetes 2025; 16(4): 102390 doi: 10.4239/wjd.v16.i4.102390
3
Juan J. Gorgojo-Martínez. Adipocentric Strategy for the Treatment of Type 2 Diabetes MellitusJournal of Clinical Medicine 2025; 14(3): 678 doi: 10.3390/jcm14030678
4
Jheng-Yan Wu, Wan-Hsuan Hsu, Chia-Chih Kuo, Ya-Wen Tsai, Ting-Hui Liu, Po-Yu Huang, Min-Hsiang Chuang, Kuo-Chuan Hung, Tsung Yu, Chih-Cheng Lai. A retrospective analysis of combination therapy with GLP-1 receptor agonists and SGLT2 inhibitors versus SGLT2 inhibitor monotherapy in patients with MASLDNature Communications 2025; 16(1) doi: 10.1038/s41467-025-62891-8